Calaspargase Pegol On The Coagulation System In Pediatric Acute Lymphoblastic Leukemia (ALL) Patients

Overview

About this study

The purpose of this study is to evaluate the impact of Calaspargase Pegol (Cal-PEG) on the coagulation system in Pediatric Acute Lymphoblastic Leukemia (ALL) patients.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 0-21.5 years

  • Confirmed diagnosis of acute lymphoblastic leukemia/lymphoma

  • Planned treatment with Cal-PEG

  • Informed consent obtained from parents or guardians

Exclusion Criteria: 

  • Pre-existing coagulation disorders

  • Known hypersensitivity to asparaginase products

  • Liver failure

  • Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/07/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Madeleine O'Keefe, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions